Allogene Therapeutics
ALLOALLO · Stock Price
Historical price data
Overview
Allogene Therapeutics is a clinical-stage biotech aiming to lead the next revolution in cell therapy with its AlloCAR T platform, designed to deliver scalable, on-demand treatments. The company has advanced a portfolio into Phase 2, with key catalysts in 2026, including the pivotal ALPHA3 trial in frontline large B-cell lymphoma. Its strategy leverages multiplex gene-editing and a proprietary lymphodepletion regimen to enable safe, effective, and commercially viable allogeneic therapies.
Technology Platform
The AlloCAR T Product Platform integrates TALEN® gene-editing (for TRAC and CD52 knockout), a proprietary lymphodepletion regimen (FCRx with ALLO-647), and scalable manufacturing to create 'off-the-shelf' allogeneic CAR T cell therapies from healthy donor cells.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Fludarabine + Cyclophosphamide | Large B-cell Lymphoma | Phase 2 | |
| ALLO-647 + Fludarabine + Cyclophosphamide | Relapsed/Refractory Large B Cell Lymphoma | Phase 2 | |
| ALLO-647 + Fludarabine + Cyclophosphamide | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Phase 1/2 | |
| ALLO-647 + Fludarabine + Cyclophosphamide | Relapsed/Refractory Multiple Myeloma | Phase 1/2 | |
| ALLO-647 + Fludarabine + Cyclophosphamide | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 |
Funding History
3
Company Timeline
Founded in South San Francisco, United States
IPO — $373.6M
Series A: $300.0M
PIPE: $120.0M